1.23

3.36% 0.04

Casi Pharmaceuticals Inc (CASI)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Casi Pharmaceuticals Inc stock is traded at $1.23, with a volume of 22,294. It is up +3.36% in the last 24 hours and down -28.07% over the past month. CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.

Previous Close:

$1.19

Open:

$1.21

24h Volume:

22,294

Relative Volume:

0.19

Market Cap:

$15.13M

Revenue:

$31.56M

Net Income/Loss:

$-46.89M

P/E Ratio:

-0.4056

EPS:

-3.0329

Net Cash Flow:

$-26.70M

1W Performance:

-2.38%

1M Performance:

-28.07%

6M Performance:

-35.94%

1Y Performance:

-76.57%

1-Day Range:

$1.17

$1.25

1-Week Range:

$1.12

$1.268

52-Week Range:

$1.0909

$5.31

Casi Pharmaceuticals Inc Stock (CASI) Company Profile

Name

Casi Pharmaceuticals Inc

Sector

Healthcare (1129)

Industry

Biotechnology (632)

Phone

Address

Employee

233

Twitter

Next Earnings Date

2024-11-14

Latest SEC Filings

CASI's Discussions on Twitter

Compare CASI with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CASI Casi Pharmaceuticals Inc	1.23	24.45M	31.56M	-46.89M	-26.70M	-3.0329
VRTX Vertex Pharmaceuticals Inc	426.76	107.15B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	755.90	77.46B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	436.38	58.90B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	918.92	56.55B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	198.76	42.58B	447.02M	-1.18B	-906.14M	-6.1812

Casi Pharmaceuticals Inc Stock (CASI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-18-21	Initiated	BTIG Research	Buy
Apr-26-21	Initiated	Mizuho	Buy
Oct-23-20	Initiated	Oppenheimer	Outperform
Sep-22-16	Initiated	Maxim Group	Buy
Oct-29-15	Resumed	H.C. Wainwright	Buy
Jun-23-15	Initiated	H.C. Wainwright	Buy

View All

Casi Pharmaceuticals Inc Stock (CASI) Latest News

Nov 19, 2025

How resilient is CASI Pharmaceuticals Inc. stock in market downturns2025 Key Lessons & Long-Term Capital Growth Strategies - newser.com

Nov 19, 2025

How CASI Pharmaceuticals Inc. stock performs in weak economyGap Up & Daily Growth Stock Tips - newser.com

Nov 19, 2025

How to read the order book for CASI Pharmaceuticals Inc.2025 Market Outlook & Weekly Top Gainers Alerts - newser.com

Nov 19, 2025

Is CASI Pharmaceuticals Inc. stock gaining market shareJuly 2025 Trends & Growth Oriented Trade Recommendations - newser.com

Nov 19, 2025

Is CASI Pharmaceuticals Inc. stock a top momentum playMarket Performance Summary & Weekly High Potential Alerts - newser.com

Nov 19, 2025

CASI Pharmaceuticals Appoints James Huang as Non-Executive Chairman - TipRanks

Nov 19, 2025

CASI Pharmaceuticals Announces Changes in Board Governance - Bluefield Daily Telegraph

Nov 19, 2025

CASI Pharmaceuticals (NASDAQ: CASI) appoints James Huang Non-Executive Chairman - Stock Titan

Nov 19, 2025

What MACD and RSI say about CASI Pharmaceuticals Inc.2025 Macro Impact & Fast Entry Momentum Alerts - newser.com

Nov 19, 2025

Nov 16, 2025

Smart tools for monitoring CASI Pharmaceuticals Inc.’s price actionTrade Analysis Summary & Safe Swing Trade Setups - newser.com

Nov 16, 2025

Is CASI Pharmaceuticals Inc. stock attractive for retirement portfoliosTrade Performance Summary & Consistent Profit Focused Trading Strategies - newser.com

Nov 16, 2025

Can CASI Pharmaceuticals Inc. stock resist sector downturnsBuy Signal & Expert Approved Momentum Trade Ideas - newser.com

Nov 16, 2025

Nov 15, 2025

Will CASI Pharmaceuticals Inc. stock attract more institutional investorsChart Signals & Capital Protection Trade Alerts - newser.com

Nov 15, 2025

CASI Pharmaceuticals Announces Third Quarter 2025 Business and Financial Results - ACCESS Newswire

Nov 14, 2025

CASI Pharmaceuticals (NASDAQ: CASI) reports third-quarter revenue $3.1M; net loss $10.9M - Stock Titan

Nov 14, 2025

CASI Pharmaceuticals (CASI) Projected to Post Quarterly Earnings on Friday - Defense World

Nov 14, 2025

Nov 13, 2025